SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-012695
Filing Date
2021-05-24
Accepted
2021-05-24 16:13:01
Documents
62
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 665510
2 ex31-1.htm EX-31.1 16777
3 ex32-1.htm EX-32.1 7910
  Complete submission text file 0001493152-21-012695.txt   3680671

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE endv-20210331.xml EX-101.INS 533230
5 XBRL SCHEMA FILE endv-20210331.xsd EX-101.SCH 46337
6 XBRL CALCULATION FILE endv-20210331_cal.xml EX-101.CAL 52000
7 XBRL DEFINITION FILE endv-20210331_def.xml EX-101.DEF 206973
8 XBRL LABEL FILE endv-20210331_lab.xml EX-101.LAB 337883
9 XBRL PRESENTATION FILE endv-20210331_pre.xml EX-101.PRE 267471
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 21955055
SIC: 2834 Pharmaceutical Preparations